Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Peptides ; 33(2): 317-28, 2012 Feb.
Article in English | MEDLINE | ID: mdl-22266216

ABSTRACT

We investigated the role of endogenous neuropeptide Y (NPY) system in nicotine-mediated improvement of learning and memory in rat model of Alzheimer's disease (AD). Intracerebroventricular (icv) colchicine treatment induced AD-like condition in rats and showed increased escape latency (decreased learning), and amnesic condition in probe test in Morris water maze. In these rats, nicotine (0.5mg/kg, intraperitoneal), NPY (100 ng/rat, icv) or NPY Y1 receptor agonist [Leu(31), Pro(34)]-NPY (0.04 ng/rat, icv) decreased escape latency by 54.76%, 55.81% and 44.18%, respectively, on day 4 of the acquisition. On the other hand, selective NPY Y1 receptor antagonist, BIBP3226 (icv) produced opposite effect (44.18%). In the probe test conducted at 24h time point, nicotine, NPY or [Leu(31), Pro(34)]-NPY increased the time spent by 72.72%, 44.11% and 26.47%, respectively; while BIBP3226 caused reduction (8.82%). It seems that while NPY or [Leu(31), Pro(34)]-NPY potentiated, BIBP3226 attenuated the learning and memory enhancing effects of nicotine. Brains of colchicine treated rats showed significant reduction in NPY-immunoreactivity in the nucleus accumbens shell (cells 62.23% and fibers 50%), bed nucleus of stria terminalis (fibers 71.58%), central nucleus of amygdala (cells 74.33%), arcuate nucleus (cells 70.97% and fibers 69.65%) and dentate gyrus (cells 58.54%). However, in these rats nicotine treatment for 4 days restored NPY-immunoreactivity to the control level. We suggest that NPY, perhaps acting via NPY Y1 receptors, might interact with the endogenous cholinergic system and play a role in improving the learning and memory processes in the rats with AD-like condition.


Subject(s)
Alzheimer Disease/drug therapy , Memory/drug effects , Nicotine/pharmacology , Nicotinic Agonists/pharmacology , Receptors, Neuropeptide Y/metabolism , Alzheimer Disease/chemically induced , Alzheimer Disease/metabolism , Amygdala/drug effects , Amygdala/metabolism , Amygdala/pathology , Analysis of Variance , Animals , Arcuate Nucleus of Hypothalamus/drug effects , Arcuate Nucleus of Hypothalamus/metabolism , Arcuate Nucleus of Hypothalamus/pathology , Arginine/analogs & derivatives , Arginine/pharmacology , Colchicine , Dentate Gyrus/drug effects , Dentate Gyrus/metabolism , Dentate Gyrus/pathology , Disease Models, Animal , Escape Reaction/drug effects , Learning/drug effects , Male , Maze Learning/drug effects , Neuropeptide Y/metabolism , Neuropeptide Y/physiology , Nicotine/therapeutic use , Nicotinic Agonists/therapeutic use , Nucleus Accumbens/drug effects , Nucleus Accumbens/metabolism , Nucleus Accumbens/pathology , Rats , Rats, Sprague-Dawley , Receptors, Neuropeptide Y/agonists , Septal Nuclei/drug effects , Septal Nuclei/metabolism , Septal Nuclei/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...